1. Residual Renal Function in Hemodialysis Patients: The Role of Angiotensin-Converting Enzyme Inhibitor in Its Preservation
- Author
-
Ioannis Petrakis, Antonaki Ergini, Apostolos Papadogiannakis, Dimitris Xydakis, Konstantinos Voskarides, Eugeneios Dafnis, Konstantinos Stylianou, Konstantinos Kostakis, and Maria Sfakianaki
- Subjects
medicine.medical_specialty ,Article Subject ,biology ,business.industry ,medicine.medical_treatment ,Urology ,Renal function ,Angiotensin-converting enzyme ,urologic and male genital diseases ,Enzyme inhibitor ,Clinical Study ,biology.protein ,Medicine ,In patient ,cardiovascular diseases ,Hemodialysis ,Enalapril ,business ,Intensive care medicine ,Dialysis ,medicine.drug - Abstract
Residual Renal function (RRF) has an important role in the overall morbidity and mortality in hemodialysis patients. The role of angiotensin-converting enzyme inhibitor (ACEi) in preserving renal function in chronic proteinuric nephropathies is well documented. We test the hypothesis that enalapril (an ACEi) slows the rate of decline of RRF in patients starting hemodialysis. A prospective, randomized open-label study was carried out. 42 patients were randomized in two groups either in treatment with enalapril or no treatment at all. Our study has proven that enalapril has a significant effect on preserving residual renal function in patients starting dialysis at least during the first 12 months from the initiation of the hemodialysis. Further studies are necessary in order to investigate the potential long-term effect of ACEi on residual renal function and on morbidity and mortality in patients starting hemodialysis.
- Published
- 2013
- Full Text
- View/download PDF